24-24 April 2023
Qmed+
REGISTER NOW
keyboard_arrow_left See all news

Recent News

06 Feb, 2023 /
Qosina
Qosina Appoints Lee Pochter as Executive Vice President
Qosina Corp. announces the appointment of Lee Pochter as Executive Vice President
30 Jan, 2023 /
Cirtec Medical
Cirtec Medical Acquires QMD™ Precision Components Business
Cirtec Medical Corporation acquires QMD’s Precision Components business
27 Jan, 2023 /
AMADA WELD TECH
AMADA WELD TECH to Highlight Innovative Solutions for Medical Device Manufacturing at MD&M West 2023
Reliability, quality, and innovation on display in booth #2935
10 Jan, 2023 /
Qosina
Qosina introduces Irradiate to Order service for single-use bioprocess components
Qosina introduces an Irradiate to Order service for its single-use bioprocess component ...
09 Jan, 2023 /
Qosina
Qosina Announces Partnership with ILC Dover and Expanded Portfolio of Liquid Bag Chambers
Qosina announces a partnership with ILC Dover, a leader in the innovative design and pro...
Flexan
/ 01 May, 2018
keyboard_arrow_left See all news

Flexan, LLC Acquires IntroMed, LLC to Expand Contract Manufacturing Capabilities to Sheath Introducers

Lincolnshire, IL (April 13, 2018) – Flexan, LLC, a leading global medical device manufacturer of custom, high-precision silicone, rubber, and thermoplastic components, announced today the acquisition of IntroMed, LLC, a contract manufacturer of patent protected sheath introducers based in Salt Lake City, Utah.

“We are excited to add IntroMed’s capabilities and technology to our array of contract manufacturing services” said Jim Fitzgerald, President & CEO of Flexan, LLC. “Similar to the acquisition of MEDRON in December 2016, IntroMed has a reputation for providing innovative, high quality products and components to medical device OEM’s.”

“We are thrilled to once again partner with Flexan,” said Eric King, Managing Partner of IntroMed. “The combination with MEDRON and the rest of the Flexan organization will bring significant value to our existing and new customers”, noted Mr. King.

In late 2016, Flexan acquired Salt Lake City-based MEDRON, LLC, which offers a range of outsourced manufacturing services including high volume device production and packaging, design for manufacturability engineering support, rapid prototyping and regulatory submission assistance.

Flexan, LLC is a portfolio company of Linden Capital Partners.

About Flexan, LLC

Founded in 1946, Flexan, LLC is a global manufacturer of custom, high-precision silicone, rubber, and thermoplastic components and extrusion for a broad array of product and industry applications, primarily used in medical devices but also including hearing technology, miniature pneumatics, industrial controls, and aerospace and defense industries, among others. Flexan, LLC markets its products under the FMI, Flexan, and MEDRON brands. The FMI and MEDRON brands delivers custom contract manufacturing services including molding, extrusion and assembly for all classes of medical devices. The Flexan brand is synonymous with custom molding and expertise with molding difficult geometries as well as with bonding rubber to metal and other substrates, delivering high-precision, niche parts to a range of industries. Flexan (Suzhou) Precision Rubber Products, Ltd. is a wholly foreign owned entity in China. Suzhou manufactures products for both FMI and Flexan. Flexan, LLC sells its products worldwide and is headquartered in Lincolnshire, IL.

About IntroMed, LLC 

IntroMed was founded in 2005 by Ron Wortley, along with Dave Wortley and Eric King. IntroMed produces patent protected sheath introducers for use in catheter placements which benefit from the unique design of a movable valve.  IntroMed has earned the trust of leading medical device manufacturers for their commitment to innovation in support of the advancement of patient care which is reliant on high quality vascular access catheters. IntroMed is headquartered in Salt Lake City, UT.

 

About Linden Capital Partners

Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare industry. Linden’s strategy is based upon three elements: (i) healthcare specialization, (ii) integrated private equity and operating expertise, and (iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. For more information, please visit www.lindenllc.com.

For more information, please contact Mike Huiras at [email protected] or (224) 543-0156.

Processing. Please wait.
Loading...